Related Experiment Video

Updated: May 1, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K

[Anti-angiogenic agents of lung cancer]

Kazushige Wakuda1, Toshiaki Takahashi

  • 1Dept. of Respiratory Medicine, Shizuoka Cancer Center.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 19, 2014
PubMed

Insights

Bevacizumab, targeting vascular endothelial growth factor (VEGF), is a key anti-angiogenic therapy for nonsquamous non-small cell lung cancer. It is the only approved first-line treatment shown to extend overall survival in advanced stages.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Angiogenesis is crucial for tumor growth, making its inhibition a vital therapeutic strategy.
  • The vascular endothelial growth factor (VEGF) pathway is central to angiogenesis and tumor progression.
  • Nonsquamous non-small cell lung cancer (NSCLC) treatment is an area of active research for anti-angiogenic therapies.

Purpose:

  • To review the efficacy of bevacizumab, an anti-VEGF monoclonal antibody, in treating advanced nonsquamous NSCLC.
  • To discuss recent clinical trial results involving bevacizumab and other novel anti-angiogenic agents.
  • To highlight the role of angiogenesis inhibitors in cancer therapy.

Summary:

  • Bevacizumab targets VEGF-A, inhibiting tumor angiogenesis and demonstrating improved outcomes in phase III trials (ECOG4599, AVAiL) for nonsquamous NSCLC.
  • It is the sole approved first-line anti-angiogenic drug for advanced nonsquamous NSCLC in Japan, notably extending overall survival.
  • Newer agents targeting receptor tyrosine kinases are under investigation, but bevacizumab remains unique in its proven survival benefit.

Impact:

  • Bevacizumab has established itself as a critical treatment option for advanced nonsquamous NSCLC.
  • The findings support the continued development and clinical application of anti-angiogenic therapies.
  • This review provides insights into the current landscape and future directions for NSCLC treatment strategies.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.2K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689